Improved Glycemic Control With Intraperitoneal Versus Subcutaneous Insulin in Type 1 Diabetes
Adult
Blood Glucose
Adolescent
Injections, Subcutaneous
INJECTIONS
IMPLANTABLE PUMPS
HYPOGLYCEMIA
Young Adult
03 medical and health sciences
Insulin Infusion Systems
0302 clinical medicine
LISPRO
ABSORPTION
Humans
Insulin
METAANALYSIS
Original Research
Aged
Glycated Hemoglobin
C-Peptide
PUMP THERAPY
Incidence
Patient Selection
INFUSION
Middle Aged
Hypoglycemia
3. Good health
Diabetes Mellitus, Type 1
BLOOD-GLUCOSE STABILITY
EXTERNAL PUMPS
DOI:
10.2337/dc08-2340
Publication Date:
2009-05-09T01:30:41Z
AUTHORS (7)
ABSTRACT
OBJECTIVE
Continuous intraperitoneal insulin infusion (CIPII) with an implantable pump has been available for the past 25 years. CIPII, with its specific pharmacodynamic properties, may be a viable treatment alternative to improve glycemic control in patients with type 1 diabetes for whom other therapies have failed. There have been few studies in which CIPII was compared with subcutaneous insulin treatment for patients with type 1 diabetes with poor glycemic control.
RESEARCH DESIGN AND METHODS
In an open-label, prospective, crossover, randomized, 16-month study, the effects of CIPII and subcutaneous insulin were compared in 24 patients. The primary outcome measure was the incidence of hypoglycemia. Secondary outcome measures were A1C, and glucose profile, including time in euglycemia, as measured by continuous glucose monitoring.
RESULTS
The incidence of grade 1 hypoglycemic events was 4.0 ± 2.6 per week with subcutaneous insulin compared with 3.5 ± 2.3 per week during CIPII (P = 0.13). The absolute mean difference in A1C with CIPII compared with subcutaneous treatment was −0.76% (95% CI −1.41 to −0.11) (P = 0.03). Baseline time spent in euglycemia was 45.2 ± 12.6% and increased 10.9% (4.6–17.3) with CIPII compared with subcutaneous treatment (absolute value; P = 0.003). There were no differences in the occurrence rate for severe hypoglycemic events, daily insulin use, or BMI. No pump or catheter malfunction was observed during the study.
CONCLUSIONS
Although we did not observe a significant reduction in hypoglycemic events, improved glycemic control was achieved with the use of CIPII. We saw a 0.8% decrease in A1C and an 11% increase in the time spent in euglycemia.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (24)
CITATIONS (51)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....